Terns Completes Part 1 Enrollment of AVIATION Phase Ib NASH Clinical Trial of VAP-1 Inhibitor TERN-201

Terns Pharmaceuticals, Inc. announced the completion of patient enrollment of Part 1 of the AVIATION Trial, a Phase Ib clinical trial evaluating TERN-201, an orally-administered, highly selective inhibitor of vascular adhesion protein-1 (VAP-1), in patients with non-alcoholic steatohepatitis (NASH).